| Identification | Back Directory | [Name]
Benzeneethanol, β-[[6-chloro-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amino]-, (βR)- | [CAS]
1942843-54-0 | [Synonyms]
CDK9-IN-12
Benzeneethanol, β-[[6-chloro-5-(3-methyl-1H-indazol-5-yl)-3-pyridinyl]amino]-, (βR)- | [Molecular Formula]
C21H19ClN4O | [MOL File]
1942843-54-0.mol | [Molecular Weight]
378.86 |
| Chemical Properties | Back Directory | [Boiling point ]
654.2±55.0 °C(Predicted) | [density ]
1.368±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
13.11±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM. | [IC 50]
CDK9/cyclinT1: 5.41 nM (IC50) | [References]
[1] Han X, et al. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021 Oct 14;64(19):14647-14663. DOI:10.1021/acs.jmedchem.1c01148 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|